Ternatin and improved synthetic variants kill cancer cells by targeting the elongation factor-1A ternary complex

  1. Jordan D Carelli
  2. Steven G Sethofer
  3. Geoffrey A Smith
  4. Howard R Miller
  5. Jillian L Simard
  6. William C Merrick
  7. Rishi K Jain
  8. Nathan T Ross
  9. Jack Taunton  Is a corresponding author
  1. University of California, San Francisco, United States
  2. Novartis Institutes for BioMedical Research, United States
  3. Case Western Reserve University, United States

Abstract

Cyclic peptide natural products have evolved to exploit diverse protein targets, many of which control essential cellular processes. Inspired by a series of cyclic peptides with partially elucidated structures, we designed synthetic variants of ternatin, a cytotoxic and anti-adipogenic natural product whose molecular mode of action was unknown. The new ternatin variants are cytotoxic toward cancer cells, with up to 500-fold greater potency than ternatin itself. Using a ternatin photo-affinity probe, we identify the translation elongation factor-1A ternary complex (eEF1A∙GTP∙aminoacyl-tRNA) as a specific target and demonstrate competitive binding by the unrelated natural products, didemnin and cytotrienin. Mutations in domain III of eEF1A prevent ternatin binding and confer resistance to its cytotoxic effects, implicating the adjacent hydrophobic surface as a functional hot spot for eEF1A modulation. We conclude that the eukaryotic elongation factor-1A and its ternary complex with GTP and aminoacyl-tRNA are common targets for the evolution of cytotoxic natural products.

Article and author information

Author details

  1. Jordan D Carelli

    Chemistry and Chemical Biology Graduate Program, University of California, San Francisco, San Francisco, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Steven G Sethofer

    Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Geoffrey A Smith

    Chemistry and Chemical Biology Graduate Program, University of California, San Francisco, San Francisco, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Howard R Miller

    Novartis Institutes for BioMedical Research, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Jillian L Simard

    Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. William C Merrick

    Department of Biochemistry, School of Medicine, Case Western Reserve University, Cleveland, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Rishi K Jain

    Novartis Institutes for BioMedical Research, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Nathan T Ross

    Novartis Institutes for BioMedical Research, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Jack Taunton

    Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States
    For correspondence
    jack.taunton@ucsf.edu
    Competing interests
    The authors declare that no competing interests exist.

Copyright

© 2015, Carelli et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 5,349
    views
  • 864
    downloads
  • 48
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Citations by DOI

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Jordan D Carelli
  2. Steven G Sethofer
  3. Geoffrey A Smith
  4. Howard R Miller
  5. Jillian L Simard
  6. William C Merrick
  7. Rishi K Jain
  8. Nathan T Ross
  9. Jack Taunton
(2015)
Ternatin and improved synthetic variants kill cancer cells by targeting the elongation factor-1A ternary complex
eLife 4:e10222.
https://doi.org/10.7554/eLife.10222

Share this article

https://doi.org/10.7554/eLife.10222